Zelig Eshhar - Publications

Affiliations: 
Weizmann Institute of Science, Rehovot, Israel 
Area:
Oncology, Cell Biology, Genetics

30 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Globerson Levin A, Rawet Slobodkin M, Waks T, Horn G, Ninio-Many L, Deshet Unger N, Ohayon Y, Suliman S, Cohen Y, Tartakovsky B, Naparstek E, Avivi I, Eshhar Z. Treatment of Multiple Myeloma using Chimeric Antigen Receptor T Cells with Dual Specificity. Cancer Immunology Research. PMID 33008840 DOI: 10.1158/2326-6066.CIR-20-0118  0.44
2020 Szoor A, Toth G, Zsebik B, Szabo V, Eshhar Z, Abken H, Vereb G. Trastuzumab derived HER2-specific CARs for the treatment of trastuzumab-resistant breast cancer: CAR T cells penetrate and eradicate tumors that are not accessible to antibodies. Cancer Letters. PMID 32289441 DOI: 10.1016/j.canlet.2020.04.008  0.36
2020 Globerson Levin A, Kronik N, Shiloach T, Waks T, Eshhar Z, Vainstein V. Less is more: reducing the number of administered chimeric antigen receptor T cells in a mouse model using a mathematically guided approach. Cancer Immunology, Immunotherapy : Cii. PMID 32130452 DOI: 10.1007/s00262-020-02516-9  0.44
2018 Zupančič E, Curato C, Kim JS, Yeini E, Porat Z, Viana AS, Globerson-Levin A, Waks T, Eshhar Z, Moreira JN, Satchi-Fainaro R, Eisenbach L, Jung S, Florindo HF. Nanoparticulate vaccine inhibits tumor growth via improved T cell recruitment into melanoma and huHER2 breast cancer. Nanomedicine : Nanotechnology, Biology, and Medicine. PMID 29306001 DOI: 10.1016/j.nano.2017.12.011  0.44
2014 Blat D, Zigmond E, Alteber Z, Waks T, Eshhar Z. Suppression of murine colitis and its associated cancer by carcinoembryonic antigen-specific regulatory T cells. Molecular Therapy : the Journal of the American Society of Gene Therapy. 22: 1018-28. PMID 24686242 DOI: 10.1038/mt.2014.41  0.44
2014 Eshhar Z, Waks T, Gross G. The emergence of T-Bodies/CAR T cells Cancer Journal (United States). 20: 123-126. PMID 24667957 DOI: 10.1097/PPO.0000000000000027  0.44
2014 Globerson-Levin A, Waks T, Eshhar Z. Elimination of progressive mammary cancer by repeated administrations of chimeric antigen receptor-modified T cells. Molecular Therapy : the Journal of the American Society of Gene Therapy. 22: 1029-38. PMID 24572294 DOI: 10.1038/mt.2014.28  0.44
2014 Friedmann-Morvinski D, Waks T, Marcus A, Eshhar Z. Adoptive Cell Therapy of Systemic Metastases Using erbB-2-Specific T Cells Redirected with a Chimeric Antibody-Based Receptor Current Cancer Research. 12: 107-122. DOI: 10.1007/978-1-4614-8809-5_7  0.44
2012 Chmielewski M, Maliar A, Eshhar Z, Abken H. CAR's made it to the pancreas. Oncoimmunology. 1: 1387-1389. PMID 23243602 DOI: 10.4161/onci.22195  0.36
2012 Fishler R, Artzy-Schnirman A, Peer E, Wolchinsky R, Brener R, Waks T, Eshhar Z, Reiter Y, Sivan U. Mixed alkanethiol monolayers on submicrometric gold patterns: a controlled platform for studying cell-ligand interactions. Nano Letters. 12: 4992-6. PMID 22900991 DOI: 10.1021/nl302619p  0.44
2012 Maliar A, Servais C, Waks T, Chmielewski M, Lavy R, Altevogt P, Abken H, Eshhar Z. Redirected T cells that target pancreatic adenocarcinoma antigens eliminate tumors and metastases in mice. Gastroenterology. 143: 1375-84.e1-5. PMID 22819865 DOI: 10.1053/j.gastro.2012.07.017  0.44
2011 Artzy-Schnirman A, Blat D, Talmon Y, Fishler R, Gertman D, Oren R, Wolchinsky R, Waks T, Benhar I, Eshhar Z, Sivan U, Reiter Y. Electrically controlled molecular recognition harnessed to activate a cellular response. Nano Letters. 11: 4997-5001. PMID 21985491 DOI: 10.1021/nl202971r  0.44
2011 Marcus A, Waks T, Eshhar Z. Redirected tumor-specific allogeneic T cells for universal treatment of cancer. Blood. 118: 975-83. PMID 21653325 DOI: 10.1182/blood-2011-02-334284  0.44
2010 Hawkins RE, Gilham DE, Debets R, Eshhar Z, Taylor N, Abken H, Schumacher TN, ATTACK Consortium. Development of adoptive cell therapy for cancer: a clinical perspective. Human Gene Therapy. 21: 665-72. PMID 20408760 DOI: 10.1089/hum.2010.086  0.36
2009 Kela I, Harmelin A, Waks T, Orr-Urtreger A, Domany E, Eshhar Z. Interspecies comparison of prostate cancer gene-expression profiles reveals genes associated with aggressive tumors. The Prostate. 69: 1034-44. PMID 19343735 DOI: 10.1002/pros.20950  0.44
2009 Elinav E, Adam N, Waks T, Eshhar Z. Amelioration of colitis by genetically engineered murine regulatory T cells redirected by antigen-specific chimeric receptor. Gastroenterology. 136: 1721-31. PMID 19208357 DOI: 10.1053/j.gastro.2009.01.049  0.44
2008 Elinav E, Waks T, Eshhar Z. Redirection of regulatory T cells with predetermined specificity for the treatment of experimental colitis in mice. Gastroenterology. 134: 2014-24. PMID 18424268 DOI: 10.1053/j.gastro.2008.02.060  0.44
2008 Agemy L, Harmelin A, Waks T, Leibovitch I, Rabin T, Pfeffer MR, Eshhar Z. Irradiation enhances the metastatic potential of prostatic small cell carcinoma xenografts. The Prostate. 68: 530-9. PMID 18247403 DOI: 10.1002/pros.20702  0.44
2005 Eshhar Z, Waks T, Pinthus J. Redirecting immune cells against bone metastases: Immunotherapy of prostate cancer metastases using genetically programmed immune effector cells. Discovery Medicine. 5: 259-64. PMID 20704885  0.44
2005 Friedmann-Morvinski D, Bendavid A, Waks T, Schindler D, Eshhar Z. Redirected primary T cells harboring a chimeric receptor require costimulation for their antigen-specific activation. Blood. 105: 3087-93. PMID 15626734 DOI: 10.1182/blood-2004-09-3737  0.44
2004 Pinthus JH, Waks T, Malina V, Kaufman-Francis K, Harmelin A, Aizenberg I, Kanety H, Ramon J, Eshhar Z. Adoptive immunotherapy of prostate cancer bone lesions using redirected effector lymphocytes. The Journal of Clinical Investigation. 114: 1774-81. PMID 15599402 DOI: 10.1172/JCI22284  0.44
2003 Pinthus JH, Waks T, Kaufman-Francis K, Schindler DG, Harmelin A, Kanety H, Ramon J, Eshhar Z. Immuno-gene therapy of established prostate tumors using chimeric receptor-redirected human lymphocytes. Cancer Research. 63: 2470-6. PMID 12750268  0.44
2002 David A, Mabjeesh N, Azar I, Biton S, Engel S, Bernstein J, Romano J, Avidor Y, Waks T, Eshhar Z, Langer SZ, Lifschitz-Mercer B, Matzkin H, Rotman G, Toporik A, et al. Unusual alternative splicing within the human kallikrein genes KLK2 and KLK3 gives rise to novel prostate-specific proteins. The Journal of Biological Chemistry. 277: 18084-90. PMID 11834722 DOI: 10.1074/jbc.M102285200  0.44
2001 Eshhar Z, Waks T, Bendavid A, Schindler DG. Functional expression of chimeric receptor genes in human T cells. Journal of Immunological Methods. 248: 67-76. PMID 11223069 DOI: 10.1016/S0022-1759(00)00343-4  0.44
1997 Fitzer-Attas CJ, Schindler DG, Waks T, Eshhar Z. Direct T cell activation by chimeric single chain Fv-Syk promotes Syk-Cbl association and Cbl phosphorylation. The Journal of Biological Chemistry. 272: 8551-7. PMID 9079685 DOI: 10.1074/jbc.272.13.8551  0.44
1996 Eshhar Z, Bach N, Fitzer-Attas CJ, Gross G, Lustgarten J, Waks T, Schindler DG. The T-body approach: potential for cancer immunotherapy. Springer Seminars in Immunopathology. 18: 199-209. PMID 8908700 DOI: 10.1007/BF00820666  0.44
1995 Eshhar Z, Gross G, Waks T, Lustgarten J, Bach N, Ratner A, Treisman J, Schindler DG. T-bodies: Chimeric T-cell receptors with antibody-type specificity Methods: a Companion to Methods in Enzymology. 8: 133-142. DOI: 10.1006/meth.1995.9993  0.44
1994 Bach NL, Waks T, Schindler DG, Eshhar Z. Functional expression in mast cells of chimeric receptors with antibody specificity. Cell Biophysics. 24: 229-36. PMID 7736527 DOI: 10.1007/BF02789233  0.44
1993 Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proceedings of the National Academy of Sciences of the United States of America. 90: 720-4. PMID 8421711 DOI: 10.1073/pnas.90.2.720  0.44
1982 Eshhar Z, Waks T, Oren T, Berke G, Kaufmann Y. Cytotoxic T cell hybridomas: generation and characterization Current Topics in Microbiology and Immunology. 100: 11-18. PMID 6980088  0.44
Show low-probability matches.